drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
CMAB008; a chimeric IgG1 monoclonal antibody biologic targeting TNF-α. It binds soluble and transmembrane TNF-α to neutralize its activity, blocks TNFR1/TNFR2 signaling, downregulates NF-κB–mediated inflammatory cascades (e.g., IL-1, IL-6, adhesion molecules), reduces leukocyte trafficking, and may induce apoptosis of activated immune cells via ADCC/CDC.
nci_thesaurus_concept_id
C1789
nci_thesaurus_preferred_term
Infliximab
nci_thesaurus_definition
A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody that binds soluble and transmembrane TNF-α, neutralizing its activity and blocking TNFR1/TNFR2 signaling. This suppresses NF-κB–driven inflammatory pathways (e.g., IL-1, IL-6, adhesion molecules), reduces leukocyte trafficking, and can induce apoptosis of activated immune cells via ADCC/CDC.
drug_name
Infliximab
nct_id_drug_ref
NCT05906576